• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cannabis Stock Movers For March 5, 2024

    3/5/24 4:30:05 PM ET
    $CARA
    $CGC
    $NEPT
    $PMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CARA alert in real time by email

    GAINERS:

    • Affinor Growers (OTC:RSSFF) shares closed up 44.80% at $0.04
    • MGC Pharmaceuticals (OTC:MGCLF) shares closed up 20.02% at $0.29
    • Heritage Cannabis Holding (OTC:HERTF) shares closed up 19.39% at $0.01
    • CordovaCann (OTC:LVRLF) shares closed up 15.88% at $0.09
    • Target Group (OTC:CBDY) shares closed up 14.26% at $0.00
    • 1933 Industries (OTC:TGIFF) shares closed up 8.33% at $0.01
    • Rocky Mountain High (OTC:RMHB) shares closed up 6.67% at $0.01
    • Cresco Labs (OTC:CRLBF) shares closed up 4.35% at $1.69
    • iAnthus Capital Hldgs (OTC:ITHUF) shares closed up 4.17% at $0.02
    • Zoned Props (OTC:ZDPY) shares closed up 4.02% at $0.51
    • 22nd Century Group (NASDAQ:XXII) shares closed up 3.75% at $0.17
    • Psychemedics (NASDAQ:PMD) shares closed up 3.55% at $3.21
    • CV Sciences (OTC:CVSI) shares closed up 3.48% at $0.03

    LOSERS:

    • Green Growth Brands (OTC:GGBXF) shares closed down 99.50% at $0.00
    • Item 9 Labs (OTC:INLB) shares closed down 25.00% at $0.00
    • Body and Mind (OTC:BMMJ) shares closed down 22.62% at $0.07
    • Nextleaf Solutions (OTC:OILFF) shares closed down 13.98% at $0.10
    • Maple Leaf Green World (OTC:MGWFF) shares closed down 13.38% at $0.03
    • CNBX Pharmaceuticals (OTC:CNBX) shares closed down 13.10% at $0.01
    • Cara Therapeutics (NASDAQ:CARA) shares closed down 12.97% at $0.87
    • 4Front Ventures (OTC:FFNTF) shares closed down 11.11% at $0.09
    • C21 Investments (OTC:CXXIF) shares closed down 10.86% at $0.36
    • EnWave (OTC:NWVCF) shares closed down 9.65% at $0.21
    • Canopy Gwth (NASDAQ:CGC) shares closed down 4.64% at $2.88
    • Neptune Wellness Solns (NASDAQ:NEPT) shares closed down 4.08% at $0.38
    • CLS Holdings USA (OTC:CLSH) shares closed down 3.85% at $0.05

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CARA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CARA
    $CGC
    $NEPT
    $PMD

    CompanyDatePrice TargetRatingAnalyst
    Canopy Growth Corporation
    $CGC
    11/10/2025Sell → Hold
    The Benchmark Company
    Cara Therapeutics Inc.
    $CARA
    6/13/2024$6.00 → $1.00Buy → Hold
    Stifel
    Cara Therapeutics Inc.
    $CARA
    6/13/2024$10.00 → $1.00Buy → Hold
    Canaccord Genuity
    Cara Therapeutics Inc.
    $CARA
    6/13/2024Buy → Hold
    Needham
    Cara Therapeutics Inc.
    $CARA
    6/13/2024Buy → Neutral
    H.C. Wainwright
    Canopy Growth Corporation
    $CGC
    4/4/2023Underperform → Mkt Perform
    Bernstein
    Cara Therapeutics Inc.
    $CARA
    3/8/2023$13.00 → $6.00Neutral → Underperform
    BofA Securities
    Canopy Growth Corporation
    $CGC
    11/2/2022$1.50Underperform
    Bernstein
    More analyst ratings

    $CARA
    $CGC
    $NEPT
    $PMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canopy Growth upgraded by The Benchmark Company

    The Benchmark Company upgraded Canopy Growth from Sell to Hold

    11/10/25 8:33:16 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Cara Therapeutics downgraded by Stifel with a new price target

    Stifel downgraded Cara Therapeutics from Buy to Hold and set a new price target of $1.00 from $6.00 previously

    6/13/24 7:05:24 AM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cara Therapeutics downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Cara Therapeutics from Buy to Hold and set a new price target of $1.00 from $10.00 previously

    6/13/24 7:05:04 AM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    $CGC
    $NEPT
    $PMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Mongeau Luc bought $49,994 worth of shares (27,469 units at $1.82), increasing direct ownership by 3% to 812,368 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    9/23/25 4:15:11 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Large owner Powell Anderson Capital Partners Llc bought $305,439 worth of shares (159,700 units at $1.91) (SEC Form 4)

    4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

    12/17/24 8:29:49 PM ET
    $PMD
    Medical Specialities
    Health Care

    Large owner Powell Anderson Capital Partners Llc bought $231,849 worth of shares (86,991 units at $2.67) (SEC Form 4)

    4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

    12/12/24 8:41:51 PM ET
    $PMD
    Medical Specialities
    Health Care

    $CARA
    $CGC
    $NEPT
    $PMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

    For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

    12/23/21 9:06:12 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    FDA Approval for KORSUVA issued to CARA THERAPEUTICS INC

    Submission status for CARA THERAPEUTICS INC's drug KORSUVA (ORIG-1) with active ingredient DIFELIKEFALIN has changed to 'Approval' on 08/23/2021. Application Category: NDA, Application Number: 214916, Application Classification: Type 1 - New Molecular Entity

    8/24/21 12:36:58 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    $CGC
    $NEPT
    $PMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Yanofsky Theresa sold $11,790 worth of shares (10,434 units at $1.13), decreasing direct ownership by 14% to 63,518 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    1/2/26 4:38:18 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Lazzarato David Angelo sold $17,758 worth of shares (15,715 units at $1.13), decreasing direct ownership by 15% to 87,672 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    1/2/26 4:37:09 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Arno Andrew was granted 17,295 shares, increasing direct ownership by 9,298% to 17,481 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    11/14/25 4:58:49 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $CARA
    $CGC
    $NEPT
    $PMD
    SEC Filings

    View All

    SEC Form S-3 filed by Canopy Growth Corporation

    S-3 - Canopy Growth Corp (0001737927) (Filer)

    2/6/26 4:15:52 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Canopy Growth Corp (0001737927) (Filer)

    2/6/26 7:05:59 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Canopy Growth Corporation

    10-Q - Canopy Growth Corp (0001737927) (Filer)

    2/6/26 6:45:57 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CARA
    $CGC
    $NEPT
    $PMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Canopy Growth to Report Third Quarter Fiscal 2026 Financial Results on February 6, 2026

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) will release its financial results for the third quarter fiscal year 2026 ended December 31, 2025 before financial markets open on February 6, 2026. Following the release of its third quarter fiscal year 2026 financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO and Tom Stewart, CFO on February 6, 2026 at 10 AM Eastern Time (ET). Webcast Information A live audio webcast will be available at: https://onlinexperiences.com/Launch/QReg/ShowUUID=45C34153-5530-4D6A-A742-BC34AD2534FA Replay Information A replay will be accessible by webcast until 11:59 PM ET on May 7, 2026 at:

    1/23/26 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    2026 Asset Growth: Why Federal Compliance Is the New Metric

    VANCOUVER, British Columbia, Jan. 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – Consumer healthcare markets hit a massive $362 billion entering 2026, but smart money is shifting toward regulatory certainty rather than just market size[1]. Modern health organizations are using aggressive buyouts as a primary 2026 strategy to secure high-tech efficiency while navigating intense federal scrutiny and capital limits[2]. In this high-stakes environment, companies with a clear and proven path through federal guidelines are capturing the most attention, including Doseology Sciences Inc. (CSE:MOOD) (OTCPK:DOSEF) (FSE: VU70), Canopy Growth (NASDAQ:CGC) (TSX:WEED), Definium Therap

    1/19/26 12:20:49 PM ET
    $CGC
    $DFTX
    $KDP
    Medicinal Chemicals and Botanical Products
    Health Care
    Beverages (Production/Distribution)
    Consumer Staples

    22nd Century CEO & Chairman Larry Firestone Provides 2025 Year-in-Review Letter to Stockholders

    MOCKSVILLE, N.C., Jan. 15, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today issued the following letter to stockholders from Lawrence Firestone, the Chief Executive Officer of 22nd Century Group, Inc.:  2025 Year-in-Review Shareholder Letter Dear Shareholders, 2025 was a pivotal year for 22nd Century Group, Inc. as we exited our multi-year restructuring, began advancing our strategic initiatives, strengthened our financial foundation, and reinforced our leadership position in tobacco harm reduction. In a complex regu

    1/15/26 9:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $CARA
    $CGC
    $NEPT
    $PMD
    Financials

    Live finance-specific insights

    View All

    Canopy Growth to Report Third Quarter Fiscal 2026 Financial Results on February 6, 2026

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) will release its financial results for the third quarter fiscal year 2026 ended December 31, 2025 before financial markets open on February 6, 2026. Following the release of its third quarter fiscal year 2026 financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO and Tom Stewart, CFO on February 6, 2026 at 10 AM Eastern Time (ET). Webcast Information A live audio webcast will be available at: https://onlinexperiences.com/Launch/QReg/ShowUUID=45C34153-5530-4D6A-A742-BC34AD2534FA Replay Information A replay will be accessible by webcast until 11:59 PM ET on May 7, 2026 at:

    1/23/26 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Reports Second Quarter Fiscal 2026 Financial Results; Company Continues to Strengthen Financial Performance with Improving Adjusted EBITDA, Disciplined Cost Management, and a Stronger Balance Sheet

    Canada adult-use revenue up 30% in Q2 FY2026 and 37% year-to-date, reflecting the benefits of our focused commercial strategy and more disciplined execution Canada medical revenue up 17% in Q2 FY2026 and 15% year-to-date, marking another standout quarter for growth $298MM cash and cash equivalents, which exceeds debt balances by $70MM at September 30, 2025; as a result, conditions that previously raised substantial doubt concerning the Company's ability to continue as a going concern have been resolved Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced its financial results for the second quarter ended September 30, 2025 ("Q2 FY2026"). Al

    11/7/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group Reports Third Quarter 2025 Financial Results

    Significant Balance Sheet Improvement - Debt Free, Receives $9.5 Million in Non-Dilutive Cash VLN® and Partner VLN® Launches Underway, Rapidly Expanding Store Counts and Availability MOCKSVILLE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced results for the third quarter-ended September 30, 2025, and provided an update on recent business highlights. "The third quarter represents the launch point for a full pivot to a branded products strategy that will drive our future. Multiple brands of o

    11/4/25 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $CARA
    $CGC
    $NEPT
    $PMD
    Leadership Updates

    Live Leadership Updates

    View All

    Canopy Growth to Acquire MTL Cannabis; Transaction Expected to Create Canada's Leading Medical Cannabis Business and Enhance Capacity to Serve Growing International Demand

    This news release constitutes a "designated news release" for the purposes of Canopy Growth's prospectus supplement dated August 29, 2025 to its short form base shelf prospectus dated June 5, 2024 All financial amounts in this press release are expressed in Canadian dollars. Highly accretive business combination expected to generate significant run-rate synergies of approximately $10 million within 18 months Strengthens Canopy Growth's presence in Québec with an opportunity to expand national distribution of MTL's high-quality, budtender-recommended product portfolio2 MTL's core management team is expected to join Canopy Growth to drive cultivation excellence and enhance the Company's p

    12/15/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Announces Results of Annual General and Special Meeting of Shareholders

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, is pleased to announce today the voting results from its Annual General and Special Meeting of Shareholders convened on September 26, 2025 and adjourned to, and reconvened on, October 10, 2025 (the "Meeting"). All of the matters put forward before the Company's shareholders for consideration and approval, as set out in the Company's definitive proxy statement dated August 7, 2025 (the "Proxy Statement"), were approved by the requisite number of votes cast at the Meeting, as further detailed below. Each of t

    10/14/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Appoints Tom Stewart as Chief Financial Officer

    Appointment finalizes CFO transition and reinforces Canopy Growth's focus on operational discipline, financial stability, and long-term value creation Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, today announced that Tom Stewart has been appointed Chief Financial Officer, effective immediately. Mr. Stewart's appointment supports the continued execution of Canopy Growth's fiscal year 2026 strategy, which is marked by structural efficiency, operational and commercial focus, and disciplined capital allocation and cost management. With significant progres

    9/17/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CARA
    $CGC
    $NEPT
    $PMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Psychemedics Corporation

    SC 13D/A - PSYCHEMEDICS CORP (0000806517) (Subject)

    12/12/24 5:15:40 PM ET
    $PMD
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psychemedics Corporation

    SC 13G/A - PSYCHEMEDICS CORP (0000806517) (Subject)

    12/6/24 9:18:20 PM ET
    $PMD
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13D/A filed by Psychemedics Corporation

    SC 13D/A - PSYCHEMEDICS CORP (0000806517) (Subject)

    12/5/24 6:04:48 PM ET
    $PMD
    Medical Specialities
    Health Care